ADC Therapeutics (ADCT) Total Debt (2020 - 2026)

ADC Therapeutics (ADCT) has reported Total Debt for 7 consecutive years, with $115.7 million the latest figure, recorded in Q1 2026.

• Quarterly Total Debt rose 1.63% year-over-year to $115.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $115.7 million (up 1.63% YoY) and the FY2025 annual result came in at $115.5 million, up 1.6% from the prior year.
• Total Debt steadied at $115.7 million in Q1 2026 per ADCT's latest filing, from $115.5 million in the prior quarter.
• Over the last five years, Total Debt for ADCT reached as high as $122.2 million in Q4 2022 and fell as low as $95.0 million in Q1 2022.
• A 5-year average of $111.7 million and a median of $113.6 million in 2024 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2022 — Total Debt soared 141.23% — and 2023, when it slipped 7.74%.
• Year by year, Total Debt stood at $122.2 million in 2022, then retreated by 7.74% to $112.7 million in 2023, then advanced by 0.8% to $113.6 million in 2024, then advanced by 1.6% to $115.5 million in 2025, then grew by 0.19% to $115.7 million in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $115.7 million, $115.5 million, and $115.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.